Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 10, 2015, Pages 766-770

  Mizuno, Suguru ^a   Hirano, Kenji ^a   Isayama, Hiroyuki ^a   Watanabe, Takeo ^a   Yamamoto, Natsuyo ^a   Nakai, Yousuke ^a   Sasahira, Naoki ^a   Tada, Minoru ^a   Omata, Masao ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bezafibrate; Drug therapy; Primary sclerosing cholangitis; Prospective study

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INTERVENTION STUDY; LIVER FUNCTION TEST; MALE; MIDDLE AGED; PRIMARY SCLEROSING CHOLANGITIS; PROSPECTIVE STUDY; TREATMENT DURATION; CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; JAPAN; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; ADULT; AGED; BEZAFIBRATE; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84942833942     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.281     Document Type: Article

References (28)

1. Angulo P, Lindor KD,. Primary sclerosing cholangitis. Hepatology. 1999; 30: 325-32.
2. Porayko MK, Wiesner RH, LaRusso NF, Ludwig J, MacCarty RL, Steiner BL, et al., Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology. 1990; 98: 1594-602.
3. Egawa H, Ueda Y, Ichida T, Teramukai S, Nakanuma Y, Onishi S, et al., Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant. 2011; 11: 518-27.
4. Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, et al., Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008; 14: 138-43.
5. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV,. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008; 14: 245-51.
6. Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H,. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci. 2014; 21: 43-50.
7. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al., High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50: 808-14.
8. Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, et al., Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res. 1999; 16: 12-8.
9. Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, et al., Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004; 29: 216-22.
10. Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al., The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008; 38: 557-64.
11. Tanaka A, Hirohara J, Nakanuma Y, Tsubouchi H, Takikawa H,. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol. 2015; 50: 675-82.
12. Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, et al., Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol. 2002; 97: 1849-51.
13. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Kamatani N,. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol. 2003; 38: 300-1.
14. Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N,. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol. 2006; 41: 686-92.
15. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, et al., Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol. 2010; 45: 758-62.
16. Lindor KD, LaRusso NF,. Primary sclerosing cholangitis. In:, Schiff ER, Sorrell MF, editors. Schiff's diseases of the liver. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 673-84.
17. Takikawa H,. Characteristics of primary sclerosing cholangitis in Japan. Hepatol Res. 2007; 37 Suppl 3: S470-3.
18. Zumoff B,. Effect of clofibrate on plasma levels of alkaline phosphatase. N Engl J Med. 1977; 297: 669.
19. Day AP, Feher MD, Chopra R, Mayne PD,. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 1993; 42: 839-42.
20. Vosper H, Khoudoli GA, Graham TL, Palmer CN,. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther. 2002; 95: 47-62.
21. Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, et al., Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res. 2007; 37: 548-56.
22. Konieczna A, Lichnovka R, Erdosova B, Ehrmann J,. The role of PPARs in MDR-a lesson from embryonic development. Neoplasma. 2009; 56: 279-83.
23. Oude Elferink RP, Ottenhoff R, van Wijland M, Smit JJ, Schinkel AH, Groen AK,. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest. 1995; 95: 31-8.
24. Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M, et al., Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2 + -superoxide dismutase in the liver. Life Sci. 1998; 63: 135-44.
25. Hirano F, Kobayashi A, Makino I,. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int Immunopharmacol. 2003; 3: 225-32.
26. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW,. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013; 58: 329-34.
27. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergguist A,. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013; 11: 841-6.
28. Tanaka A, Takikawa H,. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun. 2013; 46: 35-40.